ATRA
Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.76
+2.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.2M | 120.8M | 128.9M | 8.6M | 63.6M |
| Cost of Revenue | 534.0K | 21.2M | 21.0M | 8.9M | 270.0M |
| Gross Profit | 5.7M | 99.6M | 107.9M | (313.0K) | (206.4M) |
| Operating Expenses | |||||
| R&D Expense | 4.2M | 37.4M | 151.5M | 224.8M | 272.5M |
| SG&A Expense | 15.7M | 26.3M | 39.9M | 50.9M | 68.1M |
| General & Admin Expense | 15.7M | 26.3M | 39.9M | 50.9M | 68.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (266.6M) |
| Total Operating Expenses | 19.9M | 63.7M | 191.4M | 275.7M | 74.1M |
| Cost and Expenses | 20.4M | 84.9M | 212.4M | 284.6M | 344.1M |
| Operating Income (EBIT) | (14.2M) | 35.9M | (83.4M) | (276.0M) | (280.5M) |
| Non-Operating | |||||
| Interest Income | 436.0K | 683.0K | 2.1M | 5.4M | 3.1M |
| Interest Expense | 2.8M | 3.8M | 4.6M | 5.3M | 373.0K |
| Net Interest Income | (2.4M) | (3.1M) | (2.5M) | 141.0K | 2.7M |
| Other Non-Op Income/Expense | (2.4M) | (3.1M) | (2.0M) | (105.0K) | 52.2M |
| Non-Operating Income (excl Interest) | (391.0K) | (649.0K) | (2.6M) | (5.2M) | (52.6M) |
| EBT (Pre-Tax Income) | (16.7M) | 32.7M | (85.4M) | (276.1M) | (228.3M) |
| Income Tax Expense | 29.0K | 31.0K | (12.0K) | 15.0K | 12.0K |
| Bottom Line | |||||
| Net Income | (16.7M) | 32.7M | (85.4M) | (276.1M) | (228.3M) |
| Earnings from Cont. Ops | (16.7M) | 32.7M | (85.4M) | (276.1M) | (228.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (16.7M) | 32.7M | (85.4M) | (276.1M) | (228.3M) |
| Per Share | |||||
| Basic EPS | ($1.18) | $2.61 | ($11.41) | ($65.18) | ($55.96) |
| Diluted EPS | ($1.18) | $2.57 | ($11.41) | ($65.18) | ($55.96) |
| Revenue Per Share | $0.41 | $9.63 | $17.22 | $2.02 | $15.58 |
| Shares | |||||
| Basic Shares Outstanding | 15.0M | 12.5M | 7.5M | 4.2M | 4.1M |
| Diluted Shares Outstanding | 15.0M | 12.7M | 7.5M | 4.2M | 4.1M |
| Profitability Metrics | |||||
| EBITDA | (13.6M) | 38.6M | (75.7M) | (266.0M) | (222.3M) |
| D&A | 186.0K | 2.1M | 5.1M | 4.8M | 5.7M |
| EBIT | (13.8M) | 36.5M | (80.8M) | (270.8M) | (227.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026